Science

A bizarre case of immunity against hypertension

A bizarre case of immunity against hypertension

A bizarre case of immunity against hypertension

By

High blood pressure almost always causes the heart to weaken.

Surprisingly, certain patients with a mutated PDE3A gene were immune to damage caused by hypertension.

For decades, scientists in Berlin have been studying a strange hereditary condition that causes half the people in certain families to have shockingly short fingers and abnormally high blood pressure. If left untreated, affected individuals often die of stroke by the age of 50. Researchers at the Max Delbrück Center (MDC) in Berlin discovered the origin of the condition in 2015 and were able to confirm it five years later using animal models: a mutation in the phosphodiesterase 3A (PDE3A) gene causes its encoded enzyme to become overactive, altering bone growth and causes hyperplasia of blood vessels, resulting in high blood pressure.

Immune to damage caused by hypertension

“High blood pressure almost always leads to weakening of the heart,” says Dr. Enno Klusman, head of the Anchor Signaling Laboratory at the Max Delbrück Center and scientist at the German Center for Cardiovascular Research (DZHK). As it has to pump against higher pressure, Klußmann explains, the organ tries to strengthen the left ventricle. “But ultimately, this results in a thickening of the heart muscle – known as cardiac hypertrophy – which can lead to heart failure, which greatly reduces its pumping capacity.”

Hypertensive family of short fingers

Short fingers in one family. Credit: Sylvia Bähring

However, this does not happen in hypertensive patients with short fingers and mutated PDE3A genes. “For reasons that are now partially – but still not fully – understood, their hearts seem immune to the damage normally caused by high blood pressure,” says Klußmann.

The research was carried out by scientists from the Max Delbrück Center, Charité – Universitätsmedizin Berlin and DZHK and was published in the journal Circulation. In addition to Klußmann, among the final authors were Max Delbrück Center professors Norbert Hübner and Michael Bader, as well as dr. Sylvia Bähring from the Center for Experimental and Clinical Research (ECRC), a joint institution of Charité and the Max Delbrück Center.

The team, which included 43 other researchers from Berlin, Bochum, Heidelberg, Kassel, Limburg, Lübeck, Canada and New Zealand, recently published their findings about the protective effects of the gene mutation – and why these findings could change the way heart failure occurs. heals in the future. The study has four first authors, three of whom are researchers at the Max Delbrück Center and one at the ECRC.

Normal Heart vs Mutant Heart

Cross-section through a normal heart (left), through one of the mutant hearts (middle), and through a severely hypertrophic heart (right). In the latter, the left ventricle is enlarged. Credit: Anastasiia Sholokh, MDC

Two mutations with the same effect

The scientists performed their tests on people with hypertension and brachydactyly syndrome (HTNB) – ie. high blood pressure and abnormally short fingers – as well as in rat models and heart muscle cells. The cells are grown from specially engineered stem cells known as induced pluripotent stem cells. Before testing began, the researchers altered the PDE3A gene in cells and animals to mimic the HTNB mutations.

“We encountered a previously unknown mutation of the PDE3A gene in the patients we examined,” reports Bähring. “Previous studies have always shown that the mutation in the enzyme is outside the catalytic domain – but now we found the mutation right in the center of this domain.” Surprisingly, both mutations have the same effect by making the enzyme more active than usual. This hyperactivity accelerates the degradation of one of the cell’s important signaling molecules known as cAMP (cyclic adenosine monophosphate), which is involved in the contraction of heart muscle cells. “It is possible that this modification of the gene – regardless of its location – causes two or more PDE3A molecules to cluster together and thus work more efficiently,” suspects Bähring.

The proteins remain the same

The researchers used a rat model – created with CRISPR-Cas9 technology in Michael Bader’s lab at the Max Delbrück Center – to try to better understand the effects of the mutations. “We treated the animals with the agent isoproterenol, a so-called beta-receptor agonist,” says Klußmann. Such drugs are sometimes used in patients with end-stage heart failure. Isoproterenol is known to cause cardiac hypertrophy. “However, surprisingly, this happened in the genetically modified rats in a manner similar to what we observed in wild animals. Contrary to what we expected, existing hypertension did not worsen the situation,” reports Klußmann. “Their hearts were apparently protected from this effect of isoproterenol.”

In further experiments, the team investigated whether proteins in a specific signaling cascade in heart muscle cells changed as a result of the mutation, and if so, which ones. Through this chain of chemical reactions, the heart responds to adrenaline and beats faster in response to situations such as excitement. Adrenaline activates the cells’ beta receptors, causing them to produce more cAMP. PDE3A and other PDEs stop the process by chemically altering cAMP. “However, we found little difference between mutant and wild-type rats in both protein and[{” attribute=””>RNA levels,” Klußmann says.

More calcium in the cytosol

The conversion of cAMP by PDE3A does not occur just anywhere in the heart muscle cell, but near a tubular membrane system that stores calcium ions. A release of these ions into the cytosol of the cell triggers muscle contraction, thus making the heartbeat. After the contraction, the calcium is pumped back into storage by a protein complex. This process is also regulated locally by PDE.

Klußmann and his team hypothesized that because these enzymes are hyperactive in the local region around the calcium pump, there should be less cAMP – which would inhibit the pump’s activity. “In the gene-modified heart muscle cells, we actually showed that the calcium ions remain in the cytosol longer than usual,” says Dr. Maria Ercu, a member of Klußmann’s lab and one of the study’s four first authors. “This could increase the contractile force of the cells.”

Activating instead of inhibiting

“PDE3 inhibitors are currently in use for acute heart failure treatment to increase cAMP levels,” Klußmann explains. Regular therapy with these drugs would rapidly sap the heart muscle’s strength. “Our findings now suggest that not the inhibition of PDE3, but – on the contrary – the selective activation of PDE3A may be a new and vastly improved approach for preventing and treating hypertension-induced cardiac damage like hypertrophic cardiomyopathy and heart failure,” Klußmann says.

But before that can happen, he says, more light needs to be shed on the protective effects of the mutation. “We have observed that PDE3A not only becomes more active, but also that its concentration in heart muscle cells decreases,” the researcher reports, adding that it is possible that the former can be explained by oligomerization – a mechanism that involves at least two enzyme molecules working together. “In this case,” says Klußmann, “we could probably develop strategies that artificially initiate local oligomerization – thus mimicking the protective effect for the heart.”

Reference: “Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage” by Maria Ercu, Michael B. Mücke, Tamara Pallien, Lajos Markó, Anastasiia Sholokh, Carolin Schächterle, Atakan Aydin, Alexa Kidd, Stephan Walter, Yasmin Esmati, Brandon J. McMurray, Daniella F. Lato, Daniele Yumi Sunaga-Franze, Philip H. Dierks, Barbara Isabel Montesinos Flores, Ryan Walker-Gray, Maolian Gong, Claudia Merticariu, Kerstin Zühlke, Michael Russwurm, Tiannan Liu, Theda U.P. Batolomaeus, Sabine Pautz, Stefanie Schelenz, Martin Taube, Hanna Napieczynska, Arnd Heuser, Jenny Eichhorst, Martin Lehmann, Duncan C. Miller, Sebastian Diecke, Fatimunnisa Qadri, Elena Popova, Reika Langanki, Matthew A. Movsesian, Friedrich W. Herberg, Sofia K. Forslund, Dominik N. Müller, Tatiana Borodina, Philipp G. Maass, Sylvia Bähring, Norbert Hübner, Michael Bader and Enno Klussmann, 19 October 2022, Circulation.
DOI: 10.1161/CIRCULATIONAHA.122.060210





#bizarre #case #immunity #hypertension

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button